This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
In the biotechnology and drugs complex, insiders are loading up on
Synageva BioPharma(GEVA), which is focused on the discovery, development and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical needs. Insiders are buying this stock into some big-time strength here, since shares are up over 80% so far in 2012.
Synageva BioPharma has a market cap of $1.04 billion and an enterprise value of $903 million. This stock trades at a premium valuation, with a price-to-sales of 235.20 and a price-to-book of 6.85. Its estimated growth rate for this year is 78.6%, and for next year it's pegged at -51.10%. This is a cash-rich company, since the total cash position on its balance sheet is $138.92 million, and its total debt is zero.
>>5 Biotech Stocks Under $10 Set to Soar
A director and beneficial owner just
bought 886,000 shares, or about $36.5 million worth of stock, at $41.20 per share. Another director also just
bought 73,000 shares, or about $3 million worth of stock, at $41.20 per share.
From a technical perspective, GEVA is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock
triggered a major breakout trade back in late June once it started to move above some past overhead resistance at $40.38 with massive upside volume. Following that trigger, shares of GEVA pulled back briefly to around $40 a share, and then took off to hit its recent
52-week high of $49.93 a share. That move has started to push GEVA into overbought territory, since its current relative strength index reading is 80.42.
If you're in the bull camp on GEVA, then I would wait for this stock to pullback significantly since it's extended by almost ten points above its 50-day moving average of $39.28 a share, and it's almost twenty points above its 200-day moving average of $30.36 a share. Look for a buying opportunity in GEVA once it pulls back closer to its 50-day
moving average of $39.28 a share, at let's say $42 to $40 a share if we get it.